Trial
NCT03187756
Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
—
Condition
Hematopoietic Malignancies
Intervention
Cyclophosphamide
Why stopped
Procedure has become standard of care - protocol is no longer necessary
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-27